{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:57:04Z","timestamp":1768445824847,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971997"],"award-info":[{"award-number":["81971997"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cca.2025.120572","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:28:21Z","timestamp":1755930501000},"page":"120572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis"],"prefix":"10.1016","volume":"578","author":[{"given":"Wenlong","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weize","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5797-2263","authenticated-orcid":false,"given":"Mingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cca.2025.120572_b0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"American Association for the Study of Liver Diseases","volume":"49","author":"Rockey","year":"2009","journal-title":"Liver Biopsy. Hepatology."},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0025","article-title":"FIB-4 and APRI for cirrhosis detection in a privately insured national cohort","volume":"6","author":"Parikh","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cca.2025.120572_b0030","unstructured":"Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis - PubMed. Accessed May 20, 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/33791882\/."},{"issue":"3","key":"10.1016\/j.cca.2025.120572_b0035","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s12072-023-10636-4","article-title":"FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence","volume":"18","author":"Simbrunner","year":"2024","journal-title":"Hepatol. Int."},{"issue":"9","key":"10.1016\/j.cca.2025.120572_b0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/liv.14906","article-title":"A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis","volume":"41","author":"Xiao","year":"2021","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13531","article-title":"Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD","volume":"38","author":"Nobili","year":"2018","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.cca.2025.120572_b0050","article-title":"Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/metabo12020155","article-title":"The Role of Aspartate Transaminase to Platelet Ratio Index (APRI) for the Prediction of Non-Alcoholic Fatty Liver Disease (NAFLD) in Severely Obese Children and Adolescents","volume":"12","author":"Rigamonti","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2025.120572_b0060","article-title":"Dysregulation of Circulating FGF19 and Bile Acids in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res. Int."},{"issue":"6","key":"10.1016\/j.cca.2025.120572_b0065","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: Epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol Commun."},{"issue":"5","key":"10.1016\/j.cca.2025.120572_b0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.cca.2025.120572_b0075","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1111\/jgh.16687","article-title":"Cross-sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases","volume":"39","author":"Li","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.cca.2025.120572_b0080","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.cca.2025.120572_b0085","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.31557\/APJCP.2024.25.9.3097","article-title":"Potential Diagnostic Role of Serum Fibroblast Growth Factor-19 in Hepatocellular Carcinoma","volume":"25","author":"Rashad","year":"2024","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"10.1016\/j.cca.2025.120572_b0090","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10620-021-07042-x","article-title":"Downregulation of Serum and Distal Ileum Fibroblast Growth Factor19 in Bile Acid Diarrhoea patients","volume":"67","author":"Chang","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cca.2025.120572_b0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clnesp.2023.11.008","article-title":"Predictive value of serum fibroblast growth factor 19 and liver stiffness for intestinal failure associated liver disease-cholestasis","volume":"59","author":"Xiao","year":"2024","journal-title":"Clin Nutr ESPEN."},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.17219\/acem\/184132","article-title":"Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease","volume":"34","author":"\u0141ukawska","year":"2025","journal-title":"Adv. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.cca.2025.120572_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"European Association for the Study of the Liver","year":"2021","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.cca.2025.120572_b0110","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/infdis\/jiac315","article-title":"Longitudinal assessment of the enhanced liver fibrosis score in the era of contemporary HIV and Hepatitis C Virus Treatment","volume":"227","author":"Gardner","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cca.2025.120572_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.891398","article-title":"Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents","volume":"13","author":"Cossiga","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2023.04.021","article-title":"EASL Clinical Practice guidelines on acute-on-chronic liver failure","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cca.2025.120572_b0125","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.cca.2025.120572_b0130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-Controlled Transient Elastography Scores to Predict Liver-Related events in Steatotic Liver Disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2025.120572_b0135","doi-asserted-by":"crossref","first-page":"13462","DOI":"10.1038\/srep13462","article-title":"Expression of hepatic Fibroblast Growth factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease","volume":"5","author":"Wunsch","year":"2015","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.cca.2025.120572_b0140","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/gutjnl-2022-327498","article-title":"Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis","volume":"72","author":"Angelini","year":"2023","journal-title":"Gut"},{"issue":"47","key":"10.1016\/j.cca.2025.120572_b0150","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.3748\/wjg.v30.i47.5070","article-title":"Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Yodoshi","year":"2024","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100774","article-title":"New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD","volume":"28","author":"Torres","year":"2023","journal-title":"Ann. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0160","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1038\/s41598-023-33564-7","article-title":"TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease","volume":"13","author":"Feng","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cca.2025.120572_b0165","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/liv.14368","article-title":"Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease","volume":"40","author":"Paternostro","year":"2020","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.cca.2025.120572_b0170","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3748\/wjg.v30.i7.685","article-title":"Red cell distribution width\/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis","volume":"30","author":"Dallio","year":"2024","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.cca.2025.120572_b0175","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3390\/medicina60111854","article-title":"Use of Non-Invasive Biomarkers and Clinical Scores to Predict the Complications of Liver Cirrhosis: a Bicentric Experience","volume":"60","author":"Scarlata","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.cca.2025.120572_b0180","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.dld.2017.05.002","article-title":"AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"49","author":"Peleg","year":"2017","journal-title":"Dig. Liver Dis."},{"issue":"10","key":"10.1016\/j.cca.2025.120572_b0185","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc22-0556","article-title":"Noninvasive Fibrosis Screening in Fatty Liver Disease among Vulnerable Populations: Impact of Diabetes and Obesity on FIB-4 score Accuracy","volume":"45","author":"Kim","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5114\/ceh.2021.104543","article-title":"FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study","volume":"7","author":"Catanzaro","year":"2021","journal-title":"Clin Exp Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0195","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12876-021-02038-3","article-title":"FIB-4, APRI, and AST\/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas","volume":"21","author":"Amernia","year":"2021","journal-title":"Iran. BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.cca.2025.120572_b0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12876-023-02780-w","article-title":"AST\/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan","volume":"23","author":"Moosavy","year":"2023","journal-title":"Iran. BMC Gastroenterol."},{"issue":"3","key":"10.1016\/j.cca.2025.120572_b0205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5114\/ceh.2023.130699","article-title":"APRI and FIB-4 indices as diagnostic noninvasive scores for prediction of severe fibrosis in patients with biliary atresia","volume":"9","author":"Nagi","year":"2023","journal-title":"Clin Exp Hepatol."},{"key":"10.1016\/j.cca.2025.120572_b0210","article-title":"FIB-4 and APRI scores for progressive liver fibrosis diagnosis in children with biliary atresia","volume":"11","author":"Lyu","year":"2023","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.cca.2025.120572_b0215","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","article-title":"Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis","volume":"69","author":"Brandl","year":"2018","journal-title":"J. Hepatol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125004516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125004516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:11:52Z","timestamp":1763039512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125004516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0009898125004516"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120572","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120572"}}